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INTRODUCTION {#lary26097-sec-0006}
============

Idiopathic subglottic stenosis (iSGS) is a debilitating extrathoracic obstruction involving the lower laryngeal and upper tracheal airway. It arises without known antecedent injury or associated disease. Emerging study has demonstrated affected patients possess tightly conserved clinical demographics,[1](#lary26097-bib-0001){ref-type="ref"} histopathologic findings,[2](#lary26097-bib-0002){ref-type="ref"} anatomic injury,[3](#lary26097-bib-0003){ref-type="ref"} and physiologic impairment.[4](#lary26097-bib-0004){ref-type="ref"} Despite description of iSGS more than four decades ago,[5](#lary26097-bib-0005){ref-type="ref"} only recently has the inflammatory fibrosing phenotype been characterized at the molecular level. Data show highly upregulated activation of the inflammatory IL‐17A/IL‐23 pathway in the mucosal scar in iSGS, yet the mechanisms responsible for the characteristic demarcated airway inflammation are unknown.

In alternate pulmonary pathologies,[6](#lary26097-bib-0006){ref-type="ref"}, [7](#lary26097-bib-0007){ref-type="ref"}, [8](#lary26097-bib-0008){ref-type="ref"}, [9](#lary26097-bib-0009){ref-type="ref"} both structural and functional changes in the lung epithelium appear to be integral to fibrotic remodeling, occurring in the setting of chronic airway inflammation. Epithelial microbiota dysbiosis, with subsequent sustained host inflammation, is found in other chronic inflammatory mucosal diseases.[10](#lary26097-bib-0010){ref-type="ref"}, [11](#lary26097-bib-0011){ref-type="ref"}, [12](#lary26097-bib-0012){ref-type="ref"}, [13](#lary26097-bib-0013){ref-type="ref"}, [14](#lary26097-bib-0014){ref-type="ref"}, [15](#lary26097-bib-0015){ref-type="ref"}, [16](#lary26097-bib-0016){ref-type="ref"}, [17](#lary26097-bib-0017){ref-type="ref"}, [18](#lary26097-bib-0018){ref-type="ref"} Although the trachea is lined with respiratory epithelia, which readily support colonization by a diverse microbiome at other upper respiratory sites such as the oropharynx,[19](#lary26097-bib-0019){ref-type="ref"}, [20](#lary26097-bib-0020){ref-type="ref"} to date nothing is known of the composition of the resident microbiome of the large airway or its contribution to airway remodeling in idiopathic subglottic stenosis. Microbiological studies that rely on culture‐based techniques underestimate the diversity of species present[10](#lary26097-bib-0010){ref-type="ref"} and offer limited detection of intracellular pathogens. The application of culture‐independent approaches offers the opportunity to both provide a broader picture of tracheal microbiome composition and identify discrete pathogenic species associated with disease states.

Previously, work has demonstrated activation of the canonical IL‐23/IL‐17A pathway in the tracheal mucosa of iSGS patients, and has identified γδ T cells as the primary cellular source of IL‐17A.[21](#lary26097-bib-0021){ref-type="ref"} Given the established role of γδ T cell IL‐17A in host defense at mucosal barriers, we analyzed tissue specimens from iSGS patients for the presence of microbial pathogens. Our unbiased molecular interrogation of the tracheal microbiota of iSGS patients provides detailed nucleic acid, protein, and immunologic evidence to demonstrate *Mycobacterium* species within tracheal scar. Together with our previous work, these studies offer new insights into the pathogenesis of iSGS. They suggest that human tracheal mucosal health is highly dependent on the composition of the resident microbiota, identify a novel pathogenic role for established large airway bacteria, and offer targets for future therapeutic interventions.

MATERIALS AND METHODS {#lary26097-sec-0007}
=====================

This study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and was approved by the institutional review board (IRB) at Vanderbilt University Medical Center (IRB: 140429).

Patients {#lary26097-sec-0008}
--------

In all, 30 iSGS, 20 intubation‐related tracheal stenosis (iLTS), and 20 normal control patients were utilized for experiments (Supp. Fig. S1.). Each iSGS and immunoglobulin‐like transcripts (iLTS) diagnosis was confirmed using previously described clinical and serologic criteria.[22](#lary26097-bib-0022){ref-type="ref"} The control population consisted of patients without known tracheal pathology, malignancy, or systemic infection. Tracheal scar or freshly isolated peripheral blood mononuclear cells (PBMC) was the source of all specimens from the iSGS and iLTS patients, and normal trachea or PBMC was the source for the control patients.

Culture Independent Quantitative Polymerase Chain Reaction Profiling of Respiratory Microbime {#lary26097-sec-0009}
---------------------------------------------------------------------------------------------

### DNA Isolation {#lary26097-sec-0010}

Genomic DNA (gDNA) was extracted with the Qiagen DNAeasy extraction kit (Qiagen, Valencia, CA) according to the manufacturer\'s instructions, with slight modification as previously described.[23](#lary26097-bib-0023){ref-type="ref"}, [24](#lary26097-bib-0024){ref-type="ref"} The gDNA concentration and quality were confirmed using the Bioanalyzer 2100 system (Agilent, Santa Clara, CA). Human respiratory pathogen quantitative polymerase chain reaction (qPCR) array (Qiagen) was performed as per manufacturer\'s instructions in a StepOnePlus instrument (Applied Biosystems, Foster City, CA). Expression analysis was performed using PCR array analysis software (Qiagen).

In Situ Hybridization for Mycobacterial Gene Product GyraseA {#lary26097-sec-0011}
------------------------------------------------------------

Paraffin‐embedded iSGS and iLTS airway stenosis tissues and healthy controls (US Biomax Inc., Rockville, MD; \# RS321) were pretreated and probed for Gyrase A (Advanced Cell Diagnostics, Hayward, CA, \#436701) following a modified RNAscope 2.0 Assay\'s HD Detection Kit (Red) (Advanced Cell Diagnostics) protocol.[25](#lary26097-bib-0025){ref-type="ref"} Tissue was digested with proteinase‐K (1:100 dilution) (Sigma‐Aldrich Co., LLC. St. Louis, MO) in 20 mM Tris‐Cl (p.H. 8.0) for 5 minutes at room temperature. Experimental controls run in parallel included bacterial gene *DapB* as a negative control to assess background signal and *Homo sapiens HS‐PPIB* to assess positive signals and protocol efficacy.

Sanger Sequencing of Mycobacterial Species {#lary26097-sec-0012}
------------------------------------------

### Molecular subtyping of Mycobacterial Species {#lary26097-sec-0013}

Nested PCR analysis was performed as previously described for Mycobacterial *rpoB* [26](#lary26097-bib-0026){ref-type="ref"} (with conditions and primers listed in supplemental data \[Supp. Table S1\]). Negative and positive controls were run in parallel. Genomic DNA extracted from *M. tuberculosis* strain H37rv served as a positive control (Vircell Technologies, Granada, Spain), whereas PCR master mix inoculated with 5 μL of sterile water, and PCR master mix alone were used as negative controls.

Determination of DNA Sequence of Amplified Products {#lary26097-sec-0014}
---------------------------------------------------

The *rpoB* gene products were run on a 2% gel and purified the 360 bp band using the Qiagen QIAquick Gel Extraction kit (Qiagen) and sequenced directly on both strands in the Vanderbilt Cancer Center Core Sequencing Laboratory, Nashville, Tennessee. Alignments of the *rpoB* sequences were performed using Sequencher 5.3 software (Gene Codes Corporation, Ann Arbor, MI).

Immunogold Labeling {#lary26097-sec-0015}
-------------------

Human tracheal mucosal biopsies were obtained in the operating room and immediately fixed with chilled buffer (50 mM sodium cacodylate \[pH 7.4\]) containing 2.5% glutaraldehyde and 2.0% paraformaldehyde and placed in 4°C overnight. The samples were then prepared as previously described.[27](#lary26097-bib-0027){ref-type="ref"} Briefly, samples were blocked with 0.1% coldwater fish skin gelatin in 50 mM sodium cacodylate buffer and stained with rabbit polyclonal anti‐*Mycobacterium tuberculosis* (*Mtb*) antibodies (LS‐C72966, LSBio, Inc., Seattle, WA), followed by goat anti‐rabbit IgG conjugated to 20 nm gold particles (Electron Microscopy Sciences, Hatfield, PA). Samples were washed three times with phosphate buffered saline containing 0.1% Tween 20 and analyzed with an FEI T‐12 transmission electron microscope (FEI, Hillsboro, Oregon) equipped with a side‐mounted digital camera. A total of 30 to 35 individual cells in each group were imaged to analyze subcellular architecture and presence of bacteria.

Elispot {#lary26097-sec-0016}
-------

Preparation of PBMC and 6‐kDa early secreted antigenic target (ESAT‐6) peptides,[23](#lary26097-bib-0023){ref-type="ref"} and Elispot assay were performed, as described previously.[28](#lary26097-bib-0028){ref-type="ref"} The number of specific interferon gamma (IFN‐γ) secreting T cells was calculated by subtracting the mean negative control value from the mean spot‐forming cell (SFC) count for duplicate wells inoculated with peptide. Negative controls always had \< 50 SFC per 10^6^ input cells. A positive response was defined as a concentration of at least 50 SFC/10^6^ PBMC, which is at least three times higher than the background level. Research assistants were blind to the clinical diagnoses of the study participants throughout the analysis.

Statistical Analysis {#lary26097-sec-0017}
--------------------

Statistical significance was set at a *P* value less than 0.05, and a mean difference equal to or greater than two‐fold change in expression levels. Normal distribution of the variables was tested using the Shapiro‐Wilk test. Differences between the x and y groups were determined using the Kruskal‐Wallis and Mann‐Whitney tests for normal and nonnormal distributions, respectively. Data were expressed as median ± standard deviation for nonnormal distributed variables. All statistical analyses were performed with Prism version 6.0 software (GraphPad Software Inc., La Jolla, CA).

RESULTS {#lary26097-sec-0018}
=======

Culture‐Independent Profiling of Respiratory Microbial Flora {#lary26097-sec-0019}
------------------------------------------------------------

Given the role of γδ T cell IL‐17A in host defense against pathogens at epithelial and mucosal barriers, we analyzed tissue specimens from iSGS patients for the presence of microbial species. All iSGS patients (10 of 10) demonstrated PCR positivity to *Mycobacterium* species (Fig. [1](#lary26097-fig-0001){ref-type="fig"}A), whereas only two of 10 iLTS patients were positive by PCR (*P* \< 0.001). In contrast, among iLTS patients, 10 of 10 showed PCR positivity to *Acinetobacter baumannii* (an established ICU pathogen[29](#lary26097-bib-0029){ref-type="ref"}), whereas only one of 10 iSGS patients showed a positive signal for this pathogen (*P* \< 0.001).

![*Mycobacterium* species in iSGS patients. The qPCR results for panel of respiratory pathogens from 10 iSGS and 10 iLTS patients. (A) Yellow indicates positive PCR products; blue indicates negative result. Ten of 10 iSGS patients had detectable PCR products for *mycobacterium tuberculosis complex* (*MtbC*), compared with two of 10 iLTS patients (two‐tailed, chi‐squared test with continuity correction; *P* \< 0.001). (B) Representative images from in situ hybridization for RNA of *Mycobacterium* gene product *gyraseA* (arrows depicting positive signal in iSGS specimen). Accompanying summary graph depicting seven of 10 iSGS patients with detectable in situ hybridization signal, compared with one 10 iLTS and 0 of 10 controls (two‐tailed, chi‐squared test; asterisk denotes *P* \< 0.001). Immunogold labeling with an anti‐MtbC antibody and high‐resolution transmission electron microscopy analyses revealed multiple structures with associated labels that exhibit typical size (500 nm--2 μm) and shape (coccoid or bacillus) of *Mycobacterium* spp. Treatment with secondary antibody alone (not shown) or an unrelated antibody to *Haemophilus influenzae* (C) revealed sparse labeling that was significantly less than the labeling achieved with the anti‐Mtb treatment (D, E). Distribution of IFN‐γ production from ESAT‐6 stimulated peripheral blood mononuclear cells isolated from the peripheral blood of iSGS patients (red; n = 10) or healthy controls (green; n = 10). Bars represent the median (50th percentile), asterisk denotes significance (two‐tailed, Mann Whitney test; *P* \< 0.005) (F). Ctrl = control; IFN‐γ = interferon gamma; iLTS = iatrogenic laryngotracheal stenosis; iSGS = idiopathic subglottic stenosis; *MtbC* = *mycobacterium tuberculosis complex*; PCR = polymerase chain reaction; qPCR = quantitative polymerase chain reaction.](LARY-127-179-g001){#lary26097-fig-0001}

Further confirmatory testing was preformed on an additional 10 iSGS, 10 iLTS, and 10 healthy controls with in situ hybridization probing RNA expression of the specific mycobacterial virulence factor DNA gyrase subunit A.[30](#lary26097-bib-0030){ref-type="ref"} Seven of 10 iSGS specimens tested positive, predominantly in the tracheal epithelium, whereas only one of 10 iLTS specimens and 0 of 10 healthy control samples showing detectable signal (*P* = 0.03) (Fig. [1](#lary26097-fig-0001){ref-type="fig"}B).

Localization of *Mycobacterium* Species Within iSGS Tracheal Scar {#lary26097-sec-0020}
-----------------------------------------------------------------

To further investigate for *Mycobacterium* species within tracheal scar tissue, we utilized Immunogold labeling and high‐resolution transmission electron microscopy. This analysis revealed multiple structures with associated labels that exhibit typical size (500 nm--2 μm) and shape (coccoid or bacillus) of *Mycobacterium* species within the extracellular matrix (Fig. [1](#lary26097-fig-0001){ref-type="fig"}D‐E), whereas controls using secondary antibody alone (data not shown) or an unrelated antibody to *Haemophilus influenzae* (Fig. [1](#lary26097-fig-0001){ref-type="fig"}C) were negative. Digital quantification of gold labels per bacterial cell by computerized algorithm confirmed visual analysis of anti‐*Mycobacterium tuberculosis* complex (*Mtbc*) antibody binding in iSGS tissues (*P* \< 0.005) (Supp. Fig. S2).

Systemic Immunologic Response to *Mycobacterium* Antigens in iSGS {#lary26097-sec-0021}
-----------------------------------------------------------------

After detection of nucleic and amino acid signal for mycobacteria within iSGS, we sought to assess the systemic immunologic response in iSGS. Utilizing Elispot, we analyzed antigen‐specific responses of peripheral leukocytes from iSGS patients to the mycobacterial ESAT‐6. We chose ESAT‐6 peptides due to prior reports of systemic cellular immune responses to these conserved *MtbC* virulence factors in sarcoidosis.[28](#lary26097-bib-0028){ref-type="ref"}, [31](#lary26097-bib-0031){ref-type="ref"} Peripheral blood mononuclear cells from iSGS patients showed a mean IFN‐γ spot‐forming‐cell (SFC) count of 165.9 (standard error of the mean \[SEM\] ± 42.4) compared with 27.4 (SEM ± 18.1) in normal controls (*P* \< 0.0076) (Fig. [1](#lary26097-fig-0001){ref-type="fig"}F.). This IFN‐γ response suggests systemic immunologic memory to *MtbC* exposure and is consistent with a pathological role for *MtbC* in iSGS.

*Mycobacterium* Species Subtyping via Sanger Sequencing {#lary26097-sec-0022}
-------------------------------------------------------

It was not possible to subtype the *Mycobacterium* species based on the initial primers in our discovery assay; therefore, we utilized Sanger sequencing[26](#lary26097-bib-0026){ref-type="ref"} to further classify the *Mycobacterium* species in a subset of samples based on the *rpoB* gene sequence. The *rpoB* PCR yielded a product of 360 bp, which Sanger sequence analysis identified as *MtbC* in eight iSGS samples. Seven of the eight positive iSGS specimens showed consistent polymorphisms in the same locations (at 2,312 and 2,313 base pairs) (Fig. [2](#lary26097-fig-0002){ref-type="fig"}A). Whereas the predicted protein coding sequence from iSGS specimens was homologous to *Mtb* reference sequences (Fig. [2](#lary26097-fig-0002){ref-type="fig"}B), phylogenetic analysis of the amino acid sequencing suggests that rather than *Mtb*, a variant member of the *MtbC* or a closely related novel mycobacterium (Fig. [2](#lary26097-fig-0002){ref-type="fig"}C) is present in iSGS specimens.

![Sanger sequencing of Mycobacterium species. Sanger sequencing of the *mycobacterium rpoB* gene in iSGS scar demonstrating 99% positional identity with *MtbC* in eight of 20 iSGS samples. (A) Seven of the eight positive samples demonstrated two identical synonymous substitutions at positions 2312 and 2313. (B) Predicted identical *rpoB* amino acid sequence in *MtbC* and iSGS specimens. Analysis of *rpoB* DNA sequences from 29 *Mycobacterium* species and from patients with iSGS showing distinct clustering of iSGS samples. Phylograms based on nucleotide alignments were generated with HKY85 distances matrices using Paup 4.0b10 (Sinauer Associates, Sunderland, MA). (C) Bootstrap values \> 50 (based on 500 replicates) are represented at each node. The branch length index is represented below the phylogram. iSGS = idiopathic subglottic stenosis; *MtbC* = *mycobacterium tuberculosis complex*.](LARY-127-179-g002){#lary26097-fig-0002}

DISCUSSION {#lary26097-sec-0023}
==========

We demonstrate through multiple distinct approaches the presence of *Mycobacterium* within tracheal scar of iSGS patients. Our prior findings suggest a major role for γδ T cells in the IL‐17A‐dependent tissue inflammation and fibrotic remodeling seen in the airways of iSGS patients.[21](#lary26097-bib-0021){ref-type="ref"} Given the established role for γδ T cells in the early production of IL‐17A in *MtbC* infection,[32](#lary26097-bib-0032){ref-type="ref"} and the critical role for IL‐17A in host clearance of pulmonary *MtbC,* [33](#lary26097-bib-0033){ref-type="ref"} our prior results are consistent with our current work demonstrating mycobacterial species within the airway scar of iSGS patients.

An early report describing iSGS as a clinical entity could not isolate bacterial sepcies[34](#lary26097-bib-0034){ref-type="ref"} in routine microbiologic culture. Similarly, all iSGS patients included in our study were culture‐negative. However, since this publication in 1993, culture‐independent techniques have become an established alternate methodology for identification of infectious agents. Polymerase chain reaction was used to identify the etiologic agents of bacillary angiomatosis (*Bartonella henselae*)[35](#lary26097-bib-0035){ref-type="ref"} and Whipple\'s disease (*Tropheryma whippelii*).[36](#lary26097-bib-0036){ref-type="ref"}

The use of antigen‐specific immune responses to microbial antigens has also been utilized to identify novel infectious agents, including Sin Nombre virus in hantavirus pulmonary syndrome,[37](#lary26097-bib-0037){ref-type="ref"} as well as a previously unknown coronavirus in severe acute respiratory syndrome[38](#lary26097-bib-0038){ref-type="ref"}, [39](#lary26097-bib-0039){ref-type="ref"} and *Mycobacterium* in sarcoidosis.[28](#lary26097-bib-0028){ref-type="ref"}, [40](#lary26097-bib-0040){ref-type="ref"} Peripheral blood mononuclear cells from iSGS patients that are stimulated ex vivo with mycobacterial virulence factor ESAT‐6 demonstrate a pronounced IFNγ response. This finding suggests that, despite negative culture results from iSGS specimens, mycobacterial antigens induce T‐cell‐specific responses in the blood of iSGS patients at similar frequencies to those of tuberculosis subjects.[28](#lary26097-bib-0028){ref-type="ref"} The observation of a pronounced cellular immune response to *Mycobacterium* EAST‐6 antigens in all 10 iSGS patients tested strongly supports the results from our molecular and protein analysis of iSGS scar.

The inability to identify mycobacterial microorganisms by routine histologic staining or to culture microorganisms from pathologic tissues provides caution to the establishment of a causative role for infectious agents in iSGS pathogenesis. However, based on prior microbiological experience with fastidious mycobacteria, there are several explanations for the failure to detect microbial species in iSGS in the initial reports of the disease: The bacteria may be present in quantities below the detection of histologic staining.[41](#lary26097-bib-0041){ref-type="ref"} Alternatively, the agent may have an ultraslow growth pattern that necessitates incubation periods much longer than the standard 6 weeks that cultures are held for isolation of *Mycobacterium* tuberculosis, which is similar to the time needed for isolation of *M. ulcerans*.[42](#lary26097-bib-0042){ref-type="ref"} Conversely, iSGS pathogenesis may reflect an immune response to infectious antigens and might not be dependent on actively replicating organisms, which is similar to the hypersensitivity pneumonitis that is induced by *Mycobacterium avium*.[43](#lary26097-bib-0043){ref-type="ref"}

An association between *Mycobacterium* and iSGS immunopathogenesis is supported by the detection of mycobacterial proteins and nucleic acids in iSGS scar, as well as local and peripheral cellular immune responses to mycobacterial antigens in iSGS subjects. However, it remains unresolved whether the identified mycobacterial constituents drive disease or whether inflammation per se creates a niche for the outgrowth of specific bacteria. It should be noted, however, that tracheal stenosis arising after intubation (iLTS; which also possess an inflammatory tissue phenotype in the airway) appears in our cohort to have a much lower percentage of patients with detected *Mycobacterium*. Given the disease rarity, these results will require confirmation in larger cohorts pooled from multiple institutions.

The presence of *Mycobacterium* within iSGS scar is particularly striking in light of proven association of *Mycobacterium* with otherwise healthy, older white females (the Lady Windermere syndrome).[44](#lary26097-bib-0044){ref-type="ref"} The characteristics of these patients (women without immunocompromise or underlying chronic lung disease and proven pulmonary *Mycobacterium* infection) closely mirror the iSGS population. Lady Windermere patients are predominantly Caucasian (86%) women (81%) presenting in their mid‐sixties. The dramatic demographic similarities of the two diseases (NTM pulmonary infection/Lady Windermere syndrome and iSGS) offers clinical precedent for a pathogenic role for *Mycobacterium* in the development or progression of iSGS.

Although our results demonstrate *Mycobacterium* species within the tracheal scar of iSGS patients, the role of host genetics to iSGS pathogenesis has not yet been explored. Interestingly, strong alternate evidence links host genotype to mycobacterial susceptibility via the IL‐23/IL‐17A axis. Molecular analysis of patients suffering from Mendelian susceptibility to mycobacterial disease has implicated polymorphisms in both the ligand (IL‐12B)[45](#lary26097-bib-0045){ref-type="ref"}, [46](#lary26097-bib-0046){ref-type="ref"} and receptor (IL‐12Rβ1)[47](#lary26097-bib-0047){ref-type="ref"}, [48](#lary26097-bib-0048){ref-type="ref"} responsible for IL‐17A activation. Similarly, although iSGS affects women nearly exclusively, the influence of estrogen on disease initiation and recurrence is unknown. Estrogen has been shown to directly drive IL‐23/IL‐23R signaling and increase IL‐17A production in severe asthma.[49](#lary26097-bib-0049){ref-type="ref"} The role of estrogen in promoting mycobacterial colonization/infection, or its role in accelerating the host response to pathogen, are questions meriting future study.

CONCLUSION {#lary26097-sec-0024}
==========

Although iSGS has long been considered strictly an anatomic abnormality requiring a surgical remedy, we offer the first evidence that the disease may represent a manifestation of altered local microbial flora coupled to a pathologic host inflammatory response. We demonstrate through multiple distinct approaches, a unique association of mycobacterial species and iSGS airway mucosa. Together with prior reports demonstrating significantly upregulated local IL‐17A, evidence of *Mycobacterium* species within tracheal scar offers new avenues for therapeutic intervention in iSGS patients. Several established reagents are available to inhibit the IL‐17A pathway.[50](#lary26097-bib-0050){ref-type="ref"}, [51](#lary26097-bib-0051){ref-type="ref"}, [52](#lary26097-bib-0052){ref-type="ref"} Alternatively, multiple drugs are available targeting *Mycobacterium* species. Interestingly, limited cases series supports a clinical benefit for one of these reagents in iSGS patients.[1](#lary26097-bib-0001){ref-type="ref"} The benefit of IL‐17A inhibition in the absence of pathogen control is unclear; thus, future clinical trials could test the clinical response of immunomodulation in combination with antibacterial therapy. Therefore, the implications this work may extend beyond the confines of iSGS to other disease arising at the interface of pathogen and host inflammatory response.
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Supp. Fig. S1. iSGS, iLTS, and control patient demographics utilized for study. Blue indicates sample use for identified assay.

###### 

Click here for additional data file.

###### 

Supp. Fig. S2. Digital quantification of high‐resolution transmission electron microscopy with Immunogold labeling using an anti‐MtbC antibody. Labels associated with apparent prokaryotic cells were assessed with digital algorithm and statistics were analyzed using one way ANOVA, and Student\'s t test with Welch\'s correction.

###### 

Click here for additional data file.

###### 

Supp. Table SI. For amplification of *rpoB* RNA sequences, a nested PCR analysis was performed. Negative and positive controls were run in parallel with each PCR assay. We used genomic DNA extracted from *M. tuberculosis* strain H37rv as positive controls (Vircell Technologies, Granada, Spain). We included the following as negative controls in each PCR reaction: PCR master mix inoculated with 5 μL of sterile water, and PCR master mix alone.

All reactions were performed using the Clonetech Titanium Taq DNA amplification kit.

The first round reaction was 50ul using the following thermocycling conditions:

\[94 C for 5 minutes, 35 cycles of (94 C, 62 C, 72 C, 30 seconds each), 72 C 7 minutes\].

Nested PCR followed by using 3ul of the first round product in a final reaction volume of 25ul using the following thermocycling conditions: \[94 C for 5 minutes, 40 cycles of (94 C, 68 C, 72 C, 30 seconds each), 72 C 7 minutes\].

###### 

Click here for additional data file.
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